Source of T Cells
|
T cells are derived from healthy donors. |
T cells are derived from the patient themselves. |
Manufacturing Time
|
Shorter preparation time, as cells are pre-manufactured. |
Longer preparation time, cells must be collected and engineered per patient. |
Cost
|
Potentially lower cost due to the "off-the-shelf" nature. |
Higher cost due to the personalized manufacturing process. |
Risk of Rejection
|
Higher, due to potential immune reaction against donor cells. |
Lower, as the cells are the patient’s own. |
Risk of GVHD (Graft vs. Host Disease)
|
Present, requires genetic modifications to reduce risk. |
Absent, as the cells originate from the patient. |
Scalability
|
High, as cells can be produced in large batches. |
Low, each batch is patient specific. |
Availability
|
Immediate availability for use in acute settings. |
Requires weeks to months for cell preparation. |
Clinical Applications
|
May be limited by immune compatibility issues. |
Broad applicability, especially in approved indications. |